Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06774963 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NextCure.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 14
- Study locations
NCT06774963: Recruiting Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NextCure.
NCT06774963 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by NextCure. The registered enrollment target is 145 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06774963, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by NextCure.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Primary Outcome
Incidence of AEs, SAEs, AEs meeting protocol defined DLT criteria, AEs leading to discontinuation and death, and laboratory abnormalities per NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG LNCB74
Study Locations (14)
Texas
- MD Anderson - Houston
- NEXT Oncology - San Antonio
- UT Health San Antonio - MD Anderson Cancer Center - San Antonio
Pennsylvania
- Sidney Kimmel Comprehensive Center at Jefferson - Philadelphia
- UPMC - Pittsburgh
California
- Hoag Family Cancer Institute - Newport Beach
Kentucky
- St. Elizabeth Healthcare - Edgewood
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University, Siteman Cancer Center - St Louis
New Jersey
- John Theurer Cancer Ctr at Hackensack Univ. Med Ctr. - Hackensack
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06774963 shows while recruiting
NCT06774963 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which LNCB74 is the first listed.
NCT06774963 lists 14 locations in 11 states (Texas, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT06774963 about?
NCT06774963 is a clinical study titled "A Phase 1 Study of LNCB74 in Advanced Solid Tumors". This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
What is the current status of trial NCT06774963?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2025-01-07. Estimated completion is 2026-12.
What conditions does trial NCT06774963 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Cancer.
What interventions are being tested in trial NCT06774963?
The interventions under investigation include: LNCB74 (DRUG).
Who is sponsoring clinical trial NCT06774963?
This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06774963 being conducted?
This trial has 14 study locations across California, Kentucky, Massachusetts, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06774963's enrollment target sits among peer trials
145 456th of 1224 higher than 766 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI